RTI Surgical, Inc. (NASDAQ:RTIX) issued an update on its FY17 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $0.05-0.07 for the period, compared to the Thomson Reuters consensus estimate of $0.06. The company issued revenue guidance of $274-280 million, compared to the consensus revenue estimate of $277.84 million.

RTI Surgical, Inc. (NASDAQ:RTIX) traded up $0.50 during trading hours on Friday, reaching $4.85. The company’s stock had a trading volume of 195,128 shares, compared to its average volume of 130,642. The stock has a market capitalization of $279.69, a price-to-earnings ratio of 117.50 and a beta of 1.73.

RTI Surgical (NASDAQ:RTIX) last issued its earnings results on Thursday, November 2nd. The medical equipment provider reported $0.01 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.01. RTI Surgical had a net margin of 1.01% and a return on equity of 2.35%. The company had revenue of $66.69 million for the quarter, compared to analysts’ expectations of $65.63 million. The company’s quarterly revenue was up .2% compared to the same quarter last year. research analysts expect that RTI Surgical, Inc. will post 0.05 earnings per share for the current fiscal year.

Several equities research analysts recently issued reports on the stock. BidaskClub cut shares of RTI Surgical from a buy rating to a hold rating in a report on Tuesday, August 8th. Zacks Investment Research upgraded shares of RTI Surgical from a sell rating to a hold rating in a report on Friday, October 13th.

In other RTI Surgical news, EVP John N. Varela purchased 12,000 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were acquired at an average cost of $4.85 per share, for a total transaction of $58,200.00. Following the completion of the transaction, the executive vice president now owns 47,998 shares of the company’s stock, valued at $232,790.30. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Nicholas J. Valeriani purchased 5,500 shares of the firm’s stock in a transaction on Monday, August 21st. The stock was acquired at an average price of $4.70 per share, for a total transaction of $25,850.00. Following the completion of the transaction, the director now directly owns 47,754 shares of the company’s stock, valued at approximately $224,443.80. The disclosure for this purchase can be found here. Company insiders own 4.90% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “RTI Surgical, Inc. (RTIX) Releases FY17 Earnings Guidance” was reported by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/rti-surgical-inc-rtix-releases-fy17-earnings-guidance/1676228.html.

About RTI Surgical

RTI Surgical, Inc is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties.

Receive News & Ratings for RTI Surgical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.